Sildenafil was developed by the American pharmaceutical company Pfizer at its research center in Sandwich, Kent, UK. It was originally intended as a phosphodiesterase type 5 (PDE5) inhibitor for the treatment of cardiovascular diseases, with the aim of relaxing vascular smooth muscle by releasing the bioactive substance nitric oxide, thereby dilating blood vessels and alleviating cardiovascular conditions. However, the results of the first clinical trial conducted at Morriston Hospital in Swansea did not meet expectations. Its performance was disappointing, making it unsuitable as a treatment for cardiovascular diseases.